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E-mail address: baos@ccf.org (S. Bao).REST/NRSF (the RE-1 silencing transcription factor or neuron-restrictive silencer factor) was origi-
nally identiﬁed as a transcriptional repressor of a number of neuronal-speciﬁc genes in neural stem
cells and non-neuronal cells. REST functions as a master regulator in the maintenance of neural
stem cells. During tumorigenesis, REST shows opposing roles in different type of cells. In human epi-
thelial cancers such as colon cancer, REST acts as a tumor suppressor. In contrast, REST plays an
oncogenic role in the development of brain tumors and other cancers. Abnormal upregulation of
REST has been found in medulloblastoma, neuroblastoma and glioblastoma (GBM). Recent studies
in GBMs suggest that REST exerts its oncogenic function by maintaining self-renewal potential of
glioma stem cells (GSCs).
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction by a single non-conserved nucleotide, whereas the non-canonicalThe RE-1 silencing transcription factor (REST) or neuron-restric-
tive silencer factor (NRSF) is a master transcriptional repressor
with a critical role in suppressing expression of neuronal-speciﬁc
genes. Since its original identiﬁcation in 1995 [1,2], REST has been
shown to play critical roles during embryonic development and
neurogenesis. In addition, abnormal expression or dysfunction of
REST has been associated with diverse diseases, including Down’s
syndrome, Huntington’s disease and various types of cancer. This
review will focus on the roles of REST to act as a tumor suppressor
or oncogene in diverse types of cancers.
2. The repressor complex formed by REST
REST is a Krüppel type zinc ﬁnger transcription factor containing
eight zinc ﬁngers and two repressor domains (RD1 and RD2) lo-
cated at N-terminal and C-terminal, respectively. REST protein con-
tains a DNA binding domain that is localized within the cluster of
zinc ﬁngers and usually binds to the 21-bp repressor element 1
(RE-1) in the regulatory regions of target genes. The DNA binding
domain can recognize two types of RE-1 motifs, including the
canonical RE-1 motif and non-canonical RE1 motif. The canonical
RE1 motif consists of two 10 bp conserved sequences separatedchemical Societies. Published by E
tem Cell Biology and Regen-
d Clinic, 9500 Euclid Avenue,
54.RE1 motif has variable length of insertion between these two con-
served sequences [3,4]. The canonical RE-1 motif has a higher afﬁn-
ity for REST than the non-canonical motif [5], suggesting that
tissue-speciﬁc function of REST may depend on binding to different
RE-1 motifs. Once REST binds to the RE-1 motifs in target genes, it
acts as a molecular scaffold to recruit several cofactors to its ami-
no-terminal RD1 and carboxy-terminal RD2 repression domains.
The macromolecular complexes thus generated epigenetically
modulate target gene expression. The most important transcrip-
tional co-regulators that REST recruits are CoREST and mSin3A
[6–13]. The N-terminal RD1 domain of REST interacts with mSin3A,
subsequently recruits the histone deacetylase complex (HDAC1,
HDAC2, HDAC4 and HDAC5) and a nuclear hormone receptor co-
repressor N-CoR [12,14]. Meanwhile, the C-terminal RD2 domain
of REST associates with CoREST, which also interacts with methyl-
CpG binding protein 2 (Mecp2), lysine-speciﬁc demethylase-1
(LSD1) and histone H3-lysine 9 methyltransferases G9a [15–17].
In addition, several studies have identiﬁed new members of the
REST complex, such as DNA methyltransferases (DNMTs), the
SWI/SNF complex and the chromodomain on Y-like (CDYL)
[17,18]. These studies demonstrated that REST regulates expression
of target genes through a dynamic macromolecular complex. The
composition of the repressor complexmay affect speciﬁcity of REST
regulation on target genes.
3. Regulation of REST by ubiquitination and deubiquitination
It has been well known that REST protein level is critical for cell
fate determination of neural stem or progenitor cells (NSCs orlsevier B.V. All rights reserved.
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NPCs. Although several pathways have been implicated in the
translational regulation of REST [19,20], the post-translational con-
trol mediated by ubiquitination and deubiquitination also plays
important roles in regulating protein levels of REST. During neuro-
nal differentiation, REST undergoes proteasomal degradation
through b-TrCP-mediated ubiquitination. For example, during neu-
ronal differentiation induced by retinoic acid (RA), REST protein
was reduced by the b-TrCP-mediated ubiquitination that leads to
degradation of REST [21]. However, during astrocytic differentia-
tion from neural progenitor cells, REST expression is maintained
by bone morphogenetic proteins (BMPs) to repress neuronal gene
expression [19]. The canonical Wnt pathway has also been shown
to regulate the expression of REST [20]. Interestingly, REST pro-
moter also contains an RE-1 sequence, suggesting that there may
be a negative feedback loop in regulating REST expression at the
transcriptional level. At the post-translational level, REST protein
is tightly controlled by b-TrCP through ubiquitin-proteasomal deg-
radation [22] and the HAUSP-mediated deubiquitination [23]. Two
b-TrCP binding motifs have been identiﬁed near the RD2 domain of
REST. A conserved phosphodegron near the carboxy-terminal of
REST is required for its interaction with b-TrCP [22]. Dephosphoryl-
ation of REST by treatment with k-phosphatase or phosphodegron-
mutant REST reduces its interaction with b-TrCP, resulting in in-
creased stability of REST protein. Other protein such as a telomere
binding protein TRF2 has been shown to stabilize REST in pluripo-
tent human stem cells (NTera2) by direct interaction with REST
[24]. Recently, we identiﬁed a critical deubiquitinase HAUSP (the
herpesvirus-associated ubiquitin-speciﬁc protease, also known as
USP7) that can counterbalance REST ubiquitination and prevent
NPC differentiation through deubiquitination [23]. REST protein le-
vel declines concordantly with HAUSP upon neuronal differentia-
tion and reciprocally with b-TrCP levels. Functional disruption of
HAUSP in NPCs reduces REST protein and induces neuronal differ-
entiation. In contrast, HAUSP overexpression stabilizes REST pro-
tein by overriding b-TrCP-mediated ubiquitination. We also
showed that a consensus site (310-PYSS-313) of human REST pro-
tein is required for the HAUSP-mediated REST deubiquitination.
Our studies demonstrated that HAUSP stabilizes REST through
deubiquitination and antagonizes b-TrCP in regulating REST at
the post-translational level [23]. Thus, the HAUSP-mediated







Maintenance of neural 
stem cells and 
promotion of 





Fig. 1. Post-translational control of REST by b-TrCP-mediated ubiquitination and
HAUSP-mediated deubiquitination to regulate REST protein level and its biological
roles. REST functions as a tumor suppressor in epithelial cells. But abnormal
expression or dysfunction of REST may exert oncogenic activity during brain tumor
development.sent critical regulatory mechanisms involved in the post-transla-
tional control of REST protein and its biological functions. We
proposed that deubiquitination and ubiquitination system func-
tions as ‘‘Ying-Yang’’ control system to regulate REST protein lev-
els. The net balance between the b-TrCP-mediated ubiquitination
and HAUSP-mediated deubiquitination controls REST protein lev-
els to direct cell fate determination (Fig. 1). The relative activity
of deubiquitination and ubiquitination for REST may deﬁne the
maintenance of ‘‘stemness’’ or initiation of neuronal differentia-
tion. It is likely that the abnormal regulation of REST by deubiqui-
tination and ubiquitination may be associated with tumorigenesis.4. The tumor suppressor role of REST in non-nervous tumors
As REST plays crucial roles in the regulation of gene expression,
abnormal function or genetic mutation of REST has been linked to
several cancer types. Interestingly, REST appears to have opposite
roles in non-nervous cancers and tumors in central nervous system
(CNS). REST was identiﬁed as a tumor suppressor in epithelial cells
during an RNAi-based genetic screening [25]. Functional inhibition
of REST in epithelial cells increased cellular capability for onco-
genic transformation. Consistently, genetic deletion of REST was
found to be a frequent event in colon cancer. A premature termina-
tion mutant REST-FS, which lacks the carboxyl terminus and acts
as dominant-negative isoform, also promotes anchorage-indepen-
dent growth of colon cancer cells. Normal bronchial epithelial cells
express high level of REST to block the neuroendocrine gene
expression, while some small cell lung cancers (SCLCs) express
both epithelial and neuronal markers [26,27]. In these SCLC pri-
mary tumor samples, a new REST splice variant with a 50-bp inser-
tion resulting in a truncated REST mutant was identiﬁed. Similar to
the REST-FS mutant, the truncated REST isoform also functions as a
dominant-negative inhibitor of wild type REST, causing upregula-
tion of neuronal markers in those cancer cells. In addition, the re-
duced REST expression or activity and abnormal expression of the
REST target gene glycine receptor a1 subunit were detected in
other SCLC cancer cell lines [28,29]. Based on the potential link be-
tween REST activity and human SCLCs, a recent study suggested
that the transcriptional proﬁle of SCG3 (a REST-dependent gene)
can be used as a sensitive prognostic biomarker for neuroendocrine
lung cancer [30]. In contrast to SCLC cells, most non-SCLC cells dis-
play normal levels of REST mRNA and protein. However, approxi-
mately 10% of non-SCLC cancers show loss of function of the
SWI/SNF complex, a cofactor required for REST activity, resulting
in increased expression of some neuronal genes in these cancers.
In addition to colon cancer and lung cancer, prostate cancer LNCaP
cells and breast cancer cells have been shown to have the loss of
REST function and the subsequent increase in neuroendocrine
genes expression [31–33]. Thus, in those non-nervous cancers, loss
of REST activity leads to neuroendocrine carcinoma-like tumor, a
highly aggressive type of carcinoma [34], suggesting that REST dys-
function could contribute to tumor development and malignant
progression.
The tumor suppressor role of REST in human epithelial cancers
has been further validated by other important studies [22,35].
Overexpression of b-TrCP, an E3 ubiquitin ligase responsible for
REST degradation, has been found to cause oncogenic transforma-
tion of humanmammary epithelial cells (HMECs). This transforma-
tion depends on REST degradation induced by b-TrCP. Furthermore,
REST has been shown to have the ability to repress transcription of
oncogenes. The REST co-repressor CDYL (chromodomain on Y-like)
can bridge REST and the histone methylase G9a to inhibit the
expression of proto-oncogene TrkC, which can induce oncogenic
transformation [17]. In addition to suppression of oncogene expres-
sion, REST acts as a tumor repressor in these non-neuronal cancers
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enhances the EGF-induced Akt phosphorylation, and inhibition of
PI(3)K signaling reduces the REST-shRNA-induced transformation
in HMECs [25]. Loss of REST function also enhances cell prolifera-
tion and survival by promoting Akt phosphorylation and upregula-
tion of BCL-2 expression in lung cancers and breast cancers [32,36].
Collectively, these studies have demonstrated that the critical role
of REST in human non-neuronal cells is tumor suppression and
growth inhibition. However, one most recent study using condi-
tional deletion of REST gene in the colonic crypts indicated that
REST might have a different role in mouse colon cancer develop-
ment [37]. Conditional deletion of REST gene in the colonic crypts
increased the expression of REST-targeted genes such as syt4 and
tubb3 in these cells, but showed no signiﬁcant effect on colon tu-
mor development. These ﬁndings suggest that the ablation of REST
tumor suppressor is not sufﬁcient for the development of colon tu-
mors inmice and other genetic or epigenetic alterationmight be re-
quired for the tumorigenic effect of REST deletion in mouse colon.
Further investigation on the role of REST in tumor suppression in
epithelial cells is clearly necessary.
5. The oncogenic function of REST in brain tumors
As REST plays a crucial role in the maintenance of neural stem
cells in brain, the functional signiﬁcance of REST abnormality has
been examined in several types of brain tumors, including medul-
loblastoma and glioblastoma. It has been demonstrated that REST
mainly acts as an oncogenic promoter in the development of these
brain tumors. In medulloblastoma, the most common malignant
pediatric brain tumor that was thought to arise from neural stem
cells or neural progenitor cells, REST has been shown to promote
medulloblastoma development [38,39]. REST is highly expressed
in medulloblastomas relative to fully differentiated human neuro-
nal teratocarcinomas and neural progenitor cells. Ectopic expres-
sion of REST-VP16 mutant in medulloblastoma cells signiﬁcantly
reduced tumorigenic potential of these cancer cells in mice. In
addition, inhibition of REST activity in medulloblastoma cells leads
to apoptosis. But the cellular and molecular mechanisms associ-
ated with the apoptosis induced by REST inhibition remain unclear.
A recent study showed that REST can regulate Hedgehog signaling
in a context-dependent manner during embryonic development
[40]. The Hedgehog signaling also plays an important role in regu-
lating proliferation and differentiation of neural stem cells [41].
During medulloblastoma development, the Hedgehog signaling
was found to be highly activated [42–44]. In addition, the Wnt sig-
naling pathway that controls the property of the neural stem cells
has been shown to regulate REST expression [20]. Thus, the cross
talk between REST and the hedgehog signaling or Wnt signaling
may play important roles during oncogenesis of medulloblastoma.
Notably, the effect of REST inhibition on cell survival in medullo-
blastoma cells and human epithelial cancer cells appears totally
opposite. Inhibition of REST activity promotes survival of human
epithelial cell but induces apoptosis of medulloblastoma cells. This
may partially explain the different role of REST in epithelial cancers
and brain tumors. It has been shown that REST needs cooperation
with other oncogenes to promote tumorigenesis of medulloblasto-
mas. Overexpression of REST alone in neural stem cells is not suf-
ﬁcient to induce medulloblastoma. But co-expression of REST and
oncoprotein c-Myc in neural stem cells potently induce medullo-
blastoma [45]. Thus, despite different roles of REST in varied types
of human tumors, genetic mutation or abnormal expression of
REST may contribute to only one of the initial steps of tumorigen-
esis. It seems that REST has to work with other oncogenes or onco-
genic pathways induced by genetic and/or epigenetic alterations to
push tumorigenesis.Glioblastoma multiforme (GBM) is the most common and lethal
type of primary brain tumor in adults. GBM displays remarkable
cellular heterogeneity and hierarchy with tumor-propagating cells
or glioma stem cells (GSCs) at the apex of the hierarchy. GSCs are
functionally deﬁned by self-renewal, multi-lineage differentiation
and in vivo propagation of tumor that recapitulates the cellular
hierarchy and tissue architecture of the parental GBM. Several
studies including ours demonstrated that GSCs promote tumor
angiogenesis, cancer invasion and therapeutic resistance [46–48].
It has been suggested that targeting REST for proteasomal degrada-
tion might disrupt GSCs [49]. GSCs derived from GBM primary tu-
mors express varied levels of REST [50]. However, the GSCs that
highly express REST (HR-GSCs) also have high levels of the key
GSC transcription factor SOX2 and show greater ability of tumor-
sphere formation relative to the GSCs with lower REST (LR-GSCs)
[50]. Furthermore, tumor formation assay in the GBM xenograft
model demonstrated that HR-GSCs have greater tumorigenic po-
tential in vivo. Knockdown of REST in HR-GSCs induced apoptosis
of tumor cells, resulting in reduction of tumor growth and inva-
sion. These studies suggest that the main role of REST in GSCs is
to maintain the self-renewal and tumorigenic potential of GSCs.
In neural stem cells, REST can bind to a number of regulatory re-
gions of target genes that are members of the pluripotency net-
work or Oct4/Sox2/Nanog transcriptional network [51]. In
addition, REST has been found to control the expression of several
important miRNAs (miR-124a, miR-9 and miR-132) that regulate
functions of neural stem cells and cancer stem cells in brain tu-
mors. Further studies are required to determine whether REST con-
trols the similar signaling pathway to regulate the self-renewal
potential of GSCs and NSCs.
6. Concluding remarks
Recent studies clearly showed that REST plays opposite roles in
epithelial cancers and brain tumors. REST acts as a tumor suppres-
sor to inhibit tumorigenesis in epithelial cells, while REST plays an
oncogenic role during the development of brain tumors. It is not
clear why REST play differential roles in different cell types. The
precise molecular mechanisms associated with this cell type-spe-
ciﬁc role of REST need to be further investigated. It is likely that
REST forms different dynamic repressor complex with other co-
activators in different cell types to exert its varied biological roles.
In order to better understand the functional signiﬁcance of REST in
regulating tumor development, more characterizations on tran-
scriptional and post-translational regulations of REST as well as
REST-mediated signaling pathway in different type of cells are cer-
tainly necessary. As REST plays a critical role in the development of
several malignant brain tumors, REST may be a potential therapeu-
tic target for brain tumors. However, as REST also plays crucial
roles in the maintenance of neural stem cells, it is important to de-
sign a novel therapeutic approach speciﬁcally targeting REST in
cancer cells.
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